Stock listing
NASDAQ:SION Sionna Therapeutics, Inc. Stock
Home listing (NASDAQ) of Sionna Therapeutics, Inc.
Follow Sionna Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:SION
$2.83 USD -0.15 (-4.9%)
Close on Nov 20, 2026
- Day range
- $2.76 – $3.06 USDNov 20, 2026
- Volume
- 547,657 sharesNov 20, 2026
- Market cap
- $127.8M USDAt the close on Nov 20, 2026 · price × 45.24M shares outstanding
- 52-week range
- $2.76 – $54.97 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $6.12M USDMedian day 1.00M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SION · Home | $2.825 USD | -0.145 (-4.9%) | 547,657 | $2.93 | $3.06 | $2.76 | $2.97 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SION · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.825 | -0.145 | -4.9% | $2.93 | $3.06 | $2.76 | 547,657 | |
| $2.97 | -0.10 | -3.3% | $3.07 | $3.23 | $2.89 | 515,104 | |
| $3.07 | -0.05 | -1.6% | $3.13 | $3.17 | $2.99 | 550,733 | |
| $3.12 | -0.21 | -6.3% | $3.31 | $3.356 | $3.10 | 553,297 | |
| $3.33 | -0.10 | -2.9% | $3.55 | $3.575 | $3.25 | 464,064 | |
| $3.43 | -0.27 | -7.3% | $3.66 | $3.66 | $3.39 | 411,786 | |
| $3.70 | 0.00 | 0.0% | $3.74 | $3.855 | $3.68 | 646,964 | |
| $3.70 | +0.13 | +3.6% | $3.49 | $3.80 | $3.38 | 954,688 | |
| $3.57 | +0.29 | +8.8% | $3.31 | $3.61 | $3.22 | 1,089,213 | |
| $3.28 | 0.00 | 0.0% | $3.27 | $3.355 | $3.19 | 986,926 | |
| $3.28 | -0.45 | -12.1% | $3.71 | $3.71 | $3.25 | 914,859 | |
| $3.73 | +0.08 | +2.2% | $3.72 | $3.84 | $3.52 | 686,868 | |
| $3.65 | -0.08 | -2.1% | $3.76 | $3.87 | $3.56 | 902,408 | |
| $3.73 | -0.14 | -3.6% | $3.91 | $3.935 | $3.65 | 655,262 | |
| $3.87 | -0.13 | -3.2% | $3.96 | $4.05 | $3.76 | 534,344 | |
| $4.00 | -0.04 | -1.0% | $4.05 | $4.16 | $3.97 | 574,883 | |
| $4.04 | +0.17 | +4.4% | $3.85 | $4.155 | $3.78 | 952,963 | |
| $3.87 | +0.18 | +4.9% | $3.68 | $3.905 | $3.63 | 1,000,646 | |
| $3.69 | +0.09 | +2.5% | $3.58 | $3.74 | $3.57 | 614,221 | |
| $3.60 | -0.20 | -5.3% | $3.75 | $3.816 | $3.55 | 917,700 | |
| $3.80 | -0.07 | -1.8% | $3.87 | $3.97 | $3.641 | 1,592,200 | |
| $3.87 | -0.28 | -6.7% | $4.20 | $4.31 | $3.86 | 1,557,100 | |
| $4.15 | +0.14 | +3.5% | $4.06 | $4.30 | $4.02 | 1,069,800 | |
| $4.01 | +0.12 | +3.1% | $3.93 | $4.11 | $3.84 | 1,166,200 | |
| $3.89 | -0.19 | -4.7% | $4.06 | $4.06 | $3.775 | 1,484,500 | |
| $4.08 | -0.01 | -0.2% | $4.15 | $4.30 | $4.02 | 944,600 | |
| $4.09 | -0.29 | -6.6% | $4.30 | $4.40 | $3.93 | 1,497,900 | |
| $4.38 | -0.31 | -6.6% | $4.69 | $4.795 | $4.365 | 790,400 | |
| $4.69 | -0.21 | -4.3% | $4.89 | $4.93 | $4.675 | 692,500 | |
| $4.90 | 0.00 | 0.0% | $4.93 | $5.12 | $4.83 | 633,600 | |
| $4.90 | +0.08 | +1.7% | $4.78 | $4.97 | $4.65 | 915,600 | |
| $4.82 | +0.07 | +1.5% | $4.68 | $4.87 | $4.61 | 880,100 | |
| $4.75 | -0.10 | -2.1% | $4.88 | $4.88 | $4.52 | 1,259,900 | |
| $4.85 | -0.06 | -1.2% | $4.95 | $4.96 | $4.63 | 1,097,000 | |
| $4.91 | -0.19 | -3.7% | $5.19 | $5.19 | $4.86 | 1,159,300 | |
| $5.10 | -0.16 | -3.0% | $5.26 | $5.33 | $5.03 | 1,056,700 | |
| $5.26 | +0.11 | +2.1% | $5.19 | $5.342 | $5.02 | 1,157,500 | |
| $5.15 | +0.03 | +0.6% | $5.15 | $5.19 | $5.025 | 797,500 | |
| $5.12 | -0.11 | -2.1% | $5.17 | $5.25 | $5.05 | 775,600 | |
| $5.23 | 0.00 | 0.0% | $5.28 | $5.30 | $5.09 | 1,401,500 | |
| $5.23 | -0.28 | -5.1% | $5.50 | $5.59 | $5.152 | 1,246,700 | |
| $5.51 | -0.51 | -8.5% | $6.03 | $6.12 | $5.32 | 1,668,800 | |
| $6.02 | +0.02 | +0.3% | $5.99 | $6.17 | $5.84 | 1,693,900 | |
| $6.00 | +0.04 | +0.7% | $6.00 | $6.13 | $5.70 | 2,522,700 | |
| $5.96 | -1.22 | -17.0% | $7.12 | $7.19 | $5.90 | 3,704,800 | |
| $7.18 | +0.14 | +2.0% | $7.27 | $7.73 | $7.15 | 1,476,800 | |
| $7.04 | +0.16 | +2.3% | $6.95 | $7.368 | $6.91 | 1,970,800 | |
| $6.88 | -1.38 | -16.7% | $7.87 | $8.00 | $6.85 | 2,461,800 | |
| $8.26 | +0.41 | +5.2% | $7.84 | $8.535 | $7.84 | 1,210,600 | |
| $7.85 | +0.23 | +3.0% | $7.79 | $8.03 | $7.47 | 1,208,100 | |
| $7.62 | +0.14 | +1.9% | $7.40 | $7.75 | $7.12 | 1,222,600 | |
| $7.48 | +0.18 | +2.5% | $7.27 | $7.55 | $7.169 | 766,100 | |
| $7.30 | +0.12 | +1.7% | $7.13 | $7.555 | $6.89 | 884,700 | |
| $7.18 | +0.43 | +6.4% | $6.68 | $7.22 | $6.62 | 921,800 | |
| $6.75 | -0.56 | -7.7% | $7.31 | $7.56 | $6.70 | 1,242,200 | |
| $7.31 | +0.85 | +13.2% | $6.63 | $7.35 | $6.27 | 1,590,500 | |
| $6.46 | +0.43 | +7.1% | $5.95 | $6.48 | $5.93 | 1,404,800 | |
| $6.03 | +0.16 | +2.7% | $5.87 | $6.08 | $5.75 | 1,382,300 | |
| $5.87 | -0.19 | -3.1% | $5.97 | $6.06 | $5.822 | 783,100 | |
| $6.06 | -0.11 | -1.8% | $6.14 | $6.25 | $5.97 | 773,900 | |
| $6.17 | -0.08 | -1.3% | $6.20 | $6.29 | $6.02 | 923,800 | |
| $6.25 | +0.66 | +11.8% | $5.60 | $6.30 | $5.58 | 1,973,200 | |
| $5.59 | +0.30 | +5.7% | $5.29 | $5.61 | $5.21 | 1,773,800 | |
| $5.29 | -0.23 | -4.2% | $5.54 | $5.72 | $5.27 | 1,937,800 | |
| $5.52 | -0.73 | -11.7% | $6.27 | $6.273 | $5.51 | 1,749,500 |
- Ticker
- NASDAQ:SION
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Sionna Therapeutics Reports Third Quarter 2026 Financial Results
Latest deck · Sep 14, 2026
Corporate Update (September 2026)
Corporate update · 23 slides
Latest news
Sionna Therapeutics Reports Third Quarter 2026 Financial Results
Nov 10, 2026
Closed $3.70 (+3.6%) on Nov 10, 2026
Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences
Nov 2, 2026
Closed $3.73 (-3.6%) on Nov 2, 2026
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
Oct 8, 2026
Closed $4.90 (0.0%) on Oct 9, 2026
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
Sep 14, 2026
Closed $6.88 (-16.7%) on Sep 15, 2026
Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update
Aug 10, 2026
Closed $4.50 (-91.2%) on Aug 10, 2026
Sionna Therapeutics Reports Second Quarter 2026 Financial Results
Aug 6, 2026
Closed $49.61 (+4.8%) on Aug 6, 2026
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
May 27, 2026
Closed $43.43 (+1.3%) on May 27, 2026
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
May 13, 2026
Closed $43.12 (+5.3%) on May 13, 2026
Sionna Therapeutics Reports First Quarter 2026 Financial Results
May 12, 2026
Closed $40.94 (-10.9%) on May 12, 2026
Sionna Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 34 in all · newest Nov 10, 2026 · oldest 2025
- Decks
- 11 decks · latest Sep 14, 2026
Where Sionna Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SION · Home listing · This page | NASDAQ | United States | USD |
| BOATS:SION | BOATS | United States | USD |
Valuation
Price/book 0.5× against a median of 5.0×: the lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$89.05M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.51
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Sionna Therapeutics, Inc. · NASDAQ:SION | US$127.8M | −US$89.05M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.51 |
| Zentalis Pharmaceuticals, Inc. · NASDAQ:ZNTL | US$133.6M | −US$62.81M | n/a | n/a | n/a | 0.7× | n/a | 0.2× | 1.44 |
| Starpharma Holdings Limited · ASX:SPL | US$133.4M | US$126.5M | n/a | 15.9× | n/a | 14.6× | −62.0% | 0.1× | n/a |
| IntoCell, Inc. · KRX:287840 | US$127.3M | US$109.4M | n/a | 45.9× | n/a | 8.7× | −295.9% | 0.0× | n/a |
| Yoda Pharmaceuticals Inc. · TPEX:7829 | US$127.1M | US$94.39M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| UnicoCell Biomed Co., Ltd. · TWSE:6794 | US$126.3M | US$106.5M | n/a | 117× | n/a | 5.1× | −381.5% | 0.1× | n/a |
| MacroGenics, Inc. · NASDAQ:MGNX | US$125.3M | −US$127.6M | n/a | −0.9× | n/a | 5.0× | −34.6% | 1.4× | 0.83 |
| PolyPid Ltd. · NASDAQ:PYPD | US$124.3M | US$119.3M | n/a | n/a | n/a | 23.1× | n/a | 0.3× | 0.93 |
| Compass Therapeutics, Inc. · NASDAQ:CMPX | US$123.9M | −US$29.89M | n/a | n/a | n/a | 0.9× | n/a | 0.1× | 1.22 |
| Humacyte, Inc. · NASDAQ:HUMA | US$123.7M | US$96.01M | n/a | 40.1× | n/a | 6.8× | n/a | 2.0× | 2.56 |
| Biomm SA · BMFBOVESPA:BIOM3 | US$123.5M | US$137.5M | 18.4× | 2.1× | 12.3× | 2.2× | 10.3% | 0.3× | n/a |
| Median of the others | US$125.8M | US$101.3M | 18.4× | 28.0× | 12.3× | 5.0× | −62.0% | 0.1× | 1.22 |
Forecasts
2 strong buy · 10 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 21.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.62 · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Ashley Parks | Vice President, Chief of Staff to CEO and Program Lead |
| Mike Cloonan | President and Chief Executive Officer |
| Elena Ridloff | Chief Financial Officer & Chief Business Officer |
| Erica Iorio | Vice President, Finance and Controller |
| Jen Fitzpatrick | Chief Legal Officer & Head of Program Management |
| Alison Easter | Vice President, Preclinical Safety |
| Cécile Le Camus | Vice President, Medical Affairs, Patient Advocacy, & Development Operations |
| Mara Furlow | Senior Vice President, Global Regulatory Affairs and Quality |
| Mark Trone | Senior Vice President, Head of Technical Operations |
| Roxanne McGrath | Vice President, Head of Human Resources |
| Charlotte McKee | Head of R&D & Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Paul Clancy | Chair |
| Bruce Booth | Director |
| Edd Fleming | Director |
| Jo Viney | Director |
| Josh Resnick | Director |
| Laurie Stelzer | Director |
| Lucian Iancovici | Director |
| Marcella Kuhlman Ruddy | Director |
| Mike Cloonan | President and Chief Executive Officer |
| Peter Thompson | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | +3.6% |
| Q2 2026 | Aug 6, 2026 · Before open | +4.8% |
| Q1 2026 | May 12, 2026 · Before open | −10.9% |
| Q4 2025 | Mar 19, 2026 | +5.8% |
| Q3 2025 | Nov 5, 2025 · Before open | −1.6% |
| Q2 2025 | Aug 11, 2025 · Before open | +13.4% |
| Q1 2025 | May 12, 2025 · Before open | +4.7% |
| Q4 2024 | Mar 20, 2025 | −1.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (September 2026) | Corporate update | 23 slides | Sep 14, 2026 |
| Corporate Update (August 2026) | Corporate update | 14 slides | Aug 10, 2026 |
| 49th European Cystic Fibrosis Conference 2026 | Conference | 11 slides | June 2026 |
| NACFC (North American Cystic Fibrosis Conference) 2025 | Conference | 16 slides | Mar 2, 2026 |
| Technical Presentation (2025) | Technical | 10 slides | Jun 6, 2025 |
| Investor Presentation (August 2024) | Investor deck | 20 slides | August 2024 |
| Investor Presentation (July 2024) | Investor deck | 20 slides | Jul 16, 2024 |
| 42nd Annual J.P. Morgan Healthcare Conference 2024 | Conference | 14 slides | January 2024 |
| 41st Annual J.P. Morgan Healthcare Conference (January 2023) | Conference | 17 slides | January 2023 |
| North American Cystic Fibrosis Conference 2022 | Conference | 15 slides | Dec 23, 2022 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Stifel Healthcare Conference 2022 | Conference | 16 slides | Nov 15, 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$219.2M raised · US$18 a share · Goldman Sachs & Co. LLC +3 Dealers: Goldman Sachs & Co. LLC (co-lead), TD Cowen (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead) | Feb 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Feb 6, 2025.
- Price
- US$18.00 a share
- Shares offered
- 10,588,233 shares of common stock
- Offering size
- US$190.6 million
- Underwriters' option
- Up to 1,588,234 more shares
- Underwriters
- Goldman Sachs & Co. LLC, TD Cowen, Stifel, Guggenheim Securities · In the order on the cover
- Shares delivered
- On or about Feb 10, 2025
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 12, 2024 |
| Filed publicly | Jan 17, 2025 |
| Amended once | Feb 3, 2025 |
| Shares registered with an exchange | Feb 4, 2025 |
| Declared effective by the SEC | Feb 6, 2025 |
| Final prospectus, with the price | Feb 7, 2025 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 7, 2025 |
| EFFECT · Notice that a registration is effective | Feb 6, 2025 |
| S-1MEF · Registration of more shares for the same offering | Feb 6, 2025 |
| CERT · Exchange's certificate of listing | Feb 6, 2025 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 4, 2025 |
| CORRESP · Letter to the SEC | Feb 4, 2025 |
| CORRESP · Letter to the SEC | Feb 4, 2025 |
| S-1/A · Registration statement, amended | Feb 3, 2025 |
| CORRESP · Letter to the SEC | Jan 24, 2025 |
| CORRESP · Letter to the SEC | Jan 17, 2025 |
All 16 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Jan 17, 2025 |
| UPLOAD · Letter from the SEC | Dec 10, 2024 |
| DRSLTR · Letter to the SEC with a draft | Nov 26, 2024 |
| DRS/A · Draft registration statement, amended | Nov 26, 2024 |
| UPLOAD · Letter from the SEC | Oct 10, 2024 |
| DRS · Draft registration statement | Sep 12, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 7, 2025
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of revenue | 647.0K | 668.0K | ||
| Gross profit | -647.0K | -668.0K | ||
| Research and development | 60.3M | 57.3M | 40.6M | 34.6M |
| Selling, general and administrative | 28.7M | 13.3M | 9.71M | 6.77M |
| Operating income | -89.0M | -70.6M | -50.3M | -41.4M |
| Depreciation and amortization | 647.0K | 668.0K | 583.0K | 122.0K |
| EBITDA | -88.3M | -69.9M | -49.8M | -41.3M |
| Income before tax | -75.3M | -61.7M | -47.3M | -40.2M |
| Income tax | 0 | 0 | ||
| Net income | -75.3M | -61.7M | -47.3M | -40.2M |
| Earnings per share, basic | -1.88 | -15.99 | -1.07 | -0.91 |
| Earnings per share, diluted | -1.88 | -15.99 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 58.5M | 37.8M | 38.5M | 54.8M |
| Short-term investments | 177.4M | 109.8M | 0 | 27.8M |
| Current assets | 241.4M | 151.0M | 39.2M | 83.8M |
| Property, plant and equipment | 2.23M | 2.47M | ||
| Total assets | 326.0M | 185.8M | 51.9M | 87.4M |
| Accounts payable | 769.0K | 1.19M | 719.0K | 557.0K |
| Current liabilities | 11.7M | 10.4M | 8.04M | 8.25M |
| Total debt | 8.68M | 9.75M | 10.5M | |
| Total liabilities | 19.1M | 19.1M | 166.8M | 157.3M |
| Shareholders' equity | 306.8M | -163.7M | -114.9M | -69.9M |
| Shares outstanding | 44.7M | 4.72M | 44.1M | 44.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -66.3M | -52.8M | -43.7M | -36.1M |
| Capital spending | -377.0K | -27.0K | -1.12M | -1.87M |
| Free cash flow | -66.7M | -52.8M | -44.8M | -37.9M |
| Cash from investing | -118.7M | -126.9M | 27.4M | -29.3M |
| Cash from financing | 205.7M | 179.0M | 31.0K | 110.9M |
| Change in cash | 20.7M | -733.0K | -16.3M | 45.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 9, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 17, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 14, 2026 | Management or board change | SEC |
| 8-K · Current report | Aug 10, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2026 | Meeting outcome | SEC |
| 144/A · Notice of proposed sale, amended | Jun 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 29, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 27, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 20, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 2, 2026 | Offer document | SEC |
| S-3ASR · Registration statement | Mar 2, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 2, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 2, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 31, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 21, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 20, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 30, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 26, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 4, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 26, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 26, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 19, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 16, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 13, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 4, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Apr 1, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 10, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Feb 7, 2025 | Offer document | SEC |
This page holds 200 of 234 filings. Open Filings
Cap table
Built by 6ix from Sionna Therapeutics, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 45,235,568
- Fully diluted
- 45,235,568
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 45,235,568 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 45,235,568 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least Feb 6, 2025 |
| Bruce Booth Other companies: Vigil Neuroscience Inc (Director · Since at least Jan 6, 2022); Kymera Therapeutics, Inc. (Director · Since at least Mar 12, 2021); Tectonic Therapeutic, Inc. (Director · Jun 10, 2021 – Jun 6, 2023 · Past); Dianthus Therapeutics, Inc. (Director · Jun 1, 2021 – Jun 28, 2022 · Past) | Director · Since at least Feb 6, 2025 |
| Elena Ridloff Other companies: Immunic, Inc. (Director · Since at least Aug 6, 2026); Kymera Therapeutics, Inc. (Director · Since at least Mar 12, 2021); Kronos Bio Inc (Director · Since at least Oct 8, 2020); ACADIA Pharmaceuticals Inc. (EVP and CFO · Jan 6, 2021 – Apr 29, 2021 · Past) | CFO and CBO · Since at least Feb 6, 2025 |
| Joshua Resnick Other companies: Cidara Therapeutics Inc (Director · Since at least Jan 3, 2025); PepGen Inc. (Director · Since at least Jun 20, 2024); Jade Biosciences, Inc. (Director · Jun 5, 2024 – Jun 5, 2024 · Past); Vor Biopharma Inc. (Director · May 23, 2024 – May 22, 2025 · Past) | Director · Since at least Feb 6, 2025 |
| Laurie Stelzer Other companies: MBX Biosciences, Inc. (Director · Since at least Jan 20, 2026); Spyre Therapeutics, Inc. (Chair of the Audit Committee · Since at least Nov 22, 2023); PMV Pharmaceuticals, Inc. (Chair, Board of Directors · Since at least Jun 2, 2022); Surface Oncology Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past) | Director · Since at least Feb 6, 2025 |
| Harold Edward Fleming Other companies: Upstream Bio, Inc. (Director · Since at least Oct 10, 2024); CRISPR Therapeutics AG (Director · Since at least Jun 10, 2021) | Director · Since at least Feb 6, 2025 |
| Marcella Kuhlman Ruddy Other companies: Upstream Bio, Inc. (Chief Medical Officer, Tectonic Therapeutic · Since at least Oct 10, 2024); Tectonic Therapeutic, Inc. (Chief Medical Officer · Since at least Jun 20, 2024) | Director · Since at least Feb 6, 2025 |
| Michael Cloonan Other companies: Bluebird bio Inc (Director · Since at least Jun 20, 2024); Sage Therapeutics Inc (Chief Business Officer · Apr 2, 2018 – Feb 10, 2021 · Past) | President & CEO, Director · Since at least Feb 6, 2025 |
| Peter Thompson Other companies: ARS Pharmaceuticals, Inc. (Director · Since at least Nov 5, 2026); Aspen Neuroscience, Inc. (Director · Since at least Nov 2, 2026) | Director · Since at least Apr 14, 2026 |
| Edd Fleming Other companies: Upstream Bio, Inc. (Executive Vice President, Enavate Sciences · Since at least Nov 5, 2026) | Director · Since at least Nov 5, 2026 |
All 26 people
| Person | Seat |
|---|---|
| Josh Resnick Other companies: PepGen Inc. (Non-Executive Director · Since at least Nov 4, 2026) | Director · Since at least Nov 4, 2026 |
| Alison Easter | Vice President, Preclinical Safety · Since at least Nov 4, 2026 |
| Ashley Parks | Vice President, Chief of Staff to CEO and Program Lead · Since at least Nov 4, 2026 |
| Caroline Stark Beer | Chief Business Officer · Since at least Sep 8, 2025 |
| Cécile Le Camus | Vice President, Medical Affairs, Patient Advocacy, & Development Operations · Since at least Nov 4, 2026 |
| Charlotte McKee | Head of R&D & Chief Medical Officer · Since at least Apr 27, 2026 |
| Erica Iorio | Vice President, Finance and Controller · Since at least Nov 4, 2026 |
| Jen Fitzpatrick | Chief Legal Officer & Head of Program Management · Since at least Sep 18, 2026 |
| Jennifer Fitzpatrick | CLO and Head of Program Mgmt. · Since at least Jul 6, 2026 |
| Jo Viney | Director · Since at least Mar 20, 2025 |
| Lucian Iancovici | Director · Since at least Nov 5, 2026 |
| Mara Furlow | Senior Vice President, Global Regulatory Affairs and Quality · Since at least Nov 4, 2026 |
| Mark Trone | Senior Vice President, Head of Technical Operations · Since at least Nov 4, 2026 |
| Mike Cloonan | President and Chief Executive Officer · Since at least Sep 14, 2026 |
| Paul Clancy | Chair · Since at least Nov 5, 2026 |
| Roxanne McGrath | Vice President, Head of Human Resources · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Sionna Therapeutics, Inc.